" class="no-js "lang="en-US"> CHI Memorial Medical Group - Medtech Alert
Friday, August 01, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
CHI Memorial Medical Group | Pharmtech Focus

CHI Memorial Medical Group

About CHI Memorial Medical Group

CHI Memorial Medical Group

CHI Memorial Medical Group has convenient locations throughout Southeast Tennessee and North Georgia. Our network of dedicated physicians provides quality health care for the entire family. Specialties include breast surgery, family and internal medicine, general surgery, gerontology, gynecology, infectious disease, metabolic surgery, pediatrics, pulmonology, rheumatology, thoracic surgery and urology.

Related Story

Cardiovascular

 Acticor Biotech Announces the Enrollment of the First US Patient in Its Phase 2/3 Study ACTISAVE for the Treatment of Stroke | Pharmtech Focus

Acticor Biotech Announces the Enrollment of the First US Patient in Its Phase 2/3 Study ACTISAVE for the Treatment of Stroke

September 27 2022

ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing innovative drugs for the […]